Second-Line Oxaliplatin and Irinotecan Versus Irinotecan Alone for Gemcitabine and S-1 Refractory Pancreatic Cancer
Status:
Completed
Trial end date:
2017-12-31
Target enrollment:
Participant gender:
Summary
This study is a randomized, open-label, controlled study that will compare the efficacy of
oxaliplatin in combination with irinotecan to irinotecan alone as second-line treatment for
patients with gemcitabine and S-1 refractory pancreatic cancer.